

## Ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo) Patient Referral Form

Admissions Fax # 844-878-6917

Admissions Phone # 855-WE-R-RARE (855-937-7273)

	1:					,				
	ographics Info	rmation								
Patient Name						SSN#	DOB			
Patient Address										
Primary Phone			Cellular Phone			Work Phone				
Emergency Contact Name, Relationship				Emer			ergency Contact Phone Number			
Additional Do	ocumentation	Needed								
- Copy of insurance cards - Patient face sheet w/demographics							ecent vitals including blood pressure creening for HBV infection			
	ance Informat	ion		, , , , , , , , ,						
Insurance Plan #1					Insurance Plan #2					
Subscriber Name			DOB		Subscriber Name DOB		DOB			
Policy Number	licy Number Group ID		Policy Number		Group ID					
Patient Clinic	al Informatior									
Gender	Height (inches)	Weight (lbs.)	Allergies	(food/drug)						
□M □F	l reigne (menes)	The Broad and Br								
Statement of Medical Necessity / Primary Diagnosis										
ICD10:		Description of dia								
Medication Ir	nformation / F	Prescription an	d Order	'S						
Medication: Directions:							Quantity/Refills			
Ocrevus Zunovo		Infuse SubQ per manufacturer guidelines over approximately 10 minutes.					Dispense: #1 dose + refills			
Dosing:			Date of Last Dose:					□ Other		
_	20 mg/23,00 ur	nits SubQ every 6								
Premedicatio	ns					Quant	ity/Refills			
Give premedication(s) 30 minutes prior to infus				ion			Dispense: quantity #QS			
	inophen	□ 325-650 mg P					PRN refills (unless otherwise noted)			
	ethasone	□ 20 mg PO						□ Other		
		_				Li Otilei	El other			
Diphenhydramine										
Other □Adverse Reaction Orders										
		d resume after syr								
			-	_	ume infusion after sympto					
		oblems): stop infu	sion, call 9	911 and administe	er EPHINEPHrine 0.3 mg o	r 0.15 mg IM (as de	termined by pation	ent weight).		
Prescriber Inf	formation									
Physician Name					Office Contact					
Practice Address					•					
NPI#			License # Pr			Practice Phone	ractice Phone			
Dharisian Circuit	- Described C. b. ct.	skina Danasii sal		In-t-	Inhadian Ciarri and Decit	Diamana and Market		Date		
Physician Signature Required - Substitution Permitted				Date	Physician Signature Require	eu - Dispense as Writte	· Dispense as written			